Cardiovascular Disease

Midwest CEPAC

ICER will develop a report assessing the comparative clinical effectiveness and value of icosapent ethyl (Vascepa®, Amarin Pharma) and rivaroxaban (Xarelto®, Janssen Pharmaceuticals) as additive therapies for cardiovascular disease (CVD).

For questions, please contact Ellie Adair, Program Manager, at eadair@icer-review.org.

Associated Meetings

September 26, 2019 10am - 4pm CT

University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to deliberate and vote on evidence presented in ICER's report on additive CVD therapies.


Key Dates

Associated Materials

02/22/2019 – 03/12/2019
Open Input Period

03/18/2019

03/18/2019 – 04/05/2019

03/18/2019

04/15/2019

05/20/2019

06/06/2019

07/24/2019
Draft Evidence Report

07/24/2019
Draft Voting Questions

07/24/2019 – 08/20/2019
Public Comment

09/12/2019
Revised Voting Questions

09/12/2019
Evidence Report

09/12/2019
Response to Comments

09/12/2019
Meeting Agenda

09/26/2019
Evidence Presentation

10/17/2019
Final Evidence Report and Meeting Summary

10/17/2019
Report-at-a-Glance